Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Standard; Transfer of Listing.
As previously disclosed on a Current Report on Form 8-K filed on July 29, 2022,
on July 25, 2022, Inhibikase Therapeutics, Inc. (the "Company") received a
deficiency letter from the Listing Qualifications Department (the "Staff") of
The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that its common
stock was below the minimum $1.00 per share requirement for continued inclusion
on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the
"Minimum Bid Price Requirement") based on the closing bid price of the common
stock for the 30 consecutive business days prior to the date of the notice from
Nasdaq.
On January 24, 2023, the Company received notice from Nasdaq indicating that,
while the Company has not regained compliance with the Minimum Bid Price
Requirement, Nasdaq has determined that the Company is eligible for an
additional 180-day period, or until July 24, 2023, to regain compliance.
According to the notice from Nasdaq, the Staff's determination was based on
(i) the Company meeting the continued listing requirement for the market value
of its publicly held shares and all other Nasdaq initial listing standards, with
the exception of the Minimum Bid Price Requirement, and (ii) the Company's
written notice to Nasdaq of its intention to cure the deficiency during the
second compliance period by effecting a reverse stock split, if necessary. If at
any time during this second 180-day compliance period, the closing bid price of
the common stock is at least $1.00 per share for a minimum of 10 consecutive
business days, Nasdaq will provide the Company with written confirmation of
compliance. If compliance cannot be demonstrated by July 24, 2023, Nasdaq will
provide written notification that the common stock will be delisted. At that
time, the Company may appeal Nasdaq's determination to a Hearings Panel.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
INHIBIKASE THERAPEUTICS, INC. 
